Bristol’s Fibrotic Game Plan: Promedior Acquisition Hinges On Phase II Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol’s third deal in anti-fibrosis field in past year could give it intravenous, disease-modifying candidate for myelofibrosis and idiopathic fibrosis.